Woodford funds take a 'hammering' as biotech shares are crushed

Neil Woodford

When Neil Woodford jumped ship at Invesco to start up two new funds of his own, he was hailed as a major figure in finance who could help revive the U.K.'s promising but underfunded biotech sector. Today, though, he's feeling the heat as the great biotech plunge over the last 5 months has pounded share value mercilessly. "The net asset value has taken a bit of a hammering because of the setback in markets that's been felt perhaps most significantly in the biotech sector where there's been some really big price corrections," Woodford tells FinancialNews. Woodford has also been accused of making some bad investments, particularly in the controversial case of Northwest Bio ($NWBO). The financier has invested £141 million in the troubled Northwest, which is now worth about £40 million. Story

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i